SARS-CoV2 Variant and Effect of Therapy
Viroj Wiwanitkit
Professor, Senior Consultant, Public Heath Curriculum, SurinRajabhat University, Surin, Thailand.
*Corresponding Author
Viroj Wiwanitkit
Professor, Senior Consultant, Public Heath Curriculum,
SurinRajabhat University, Surin, Thailand.
E-mail: wviroj@yahoo.com
Received: August 28, 2020; Published: August 31, 2020
Citation: Viroj Wiwanitkit. SARS-CoV2 Variant and Effect of Therapy. Int J Chronic Dis Ther.. 2020;6(1e):1. doi: dx.doi.org/10.19070/2332-2926-200009e
Copyright: VirojWiwanitkit© 2020. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.
COVID-19 is an important disease that already causes public
health problem around the world. The disease is caused by a new
pathogen, SARS - CoV2. At present, the treatment of this disease
is still based mainly on supportive and symptomatic treatments.
There is still no effective antiviral drug. Although there are many
reports on using classic drugs, immunotherapy as well as convalescent
plasma therapy for managing COVID-19, all cannot give
a favorite outcome.
A difficulty in case management is the fact that the pathogenic virus
seems genetic labile. There are many variants and the mutated
type can has new properties. The resistance to a drug is probable
and it is also a problem in immunotherapy and immunprevention.
The recent report from Hong Kong on the reinfection of
COVID-19 in a patient [1] can support the fact that the mutation
within the pathogenic virus result in a great difficulty in case
management. Basically, a mutation within a molecule can result
in molecular weight change and possible structural change. This
can result in alter phenotypic expression. This phenomenon is a
well explanation on nanopathogenesis of many medical problems
[2-5]. Regarding COVID-19, the applied classical antiviral drug
against the new virus has to adjust dosage based on the consideration
of molecular difference of the old virus and the new SARS
- CoV2 [5].
The knowledge on SARS-CoV2 variant is important. Further
molecular epidemiology study is required and the in depth nanopathogenesis
study on SARS-CoV2 variant is warranted.
References
- To KK, Hung IF, Ip JD, Chu AW, Chan WM, Tam AR, et al. COVID-19 re-infection by a phylogenetically distinct SARS-coronavirus-2 strain confirmed by whole genome sequencing. Clin Infect Dis. 2020 Aug 25:ciaa1275. PMID: 32840608.
- Joob B, Wiwanitkit V.NCF1-339 polymorphism and systemic lupus erythematosus. Ann Rheum Dis. 2019 Nov 28: annrheumdis-2019-216629. PMID: 31780525.
- Srriwijitalai W, Wiwanitkit V.Interleukin-6 -174G/C polymorphism and end-stage renal disease: Is there any role?. Saudi J Kidney Dis Transpl. 2018 May-Jun; 29(3): 747-748. PMID: 29970762.
- Yasri S, Wiwanitkit V. Methylenetetrahydrofo late reductase C677T polymorphism and schizophrenia: Effect of molecular change. J Res Med Sci. 2018 Mar 27; 23:20. PMID: 29692817.
- Yasri S, Wiwanitkit V. Dose prediction of lopinavir/ritonavir for 2019-novel coronavirus (2019-nCoV) infection based on mathematic modeling. Asian Pac J Trop Med. 2020; 13:137-8.